2. Academic Validation
  3. Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer

Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer

  • Sci Transl Med. 2016 Oct 19;8(361):361ra140. doi: 10.1126/scitranslmed.aaf8127.
Lu Zhang 1,  Panayotis C Theodoropoulos 2,  Ugur Eskiocak 3,  Wentian Wang 2,  Young-Ah Moon 4,  Bruce Posner 2,  Noelle S Williams 2,  Woodring E Wright 1,  Sang Bum Kim 1,  Deepak Nijhawan 2 5 6,  Jef K De Brabander 2,  Jerry W Shay 7
Affiliations

Affiliations

  • 1 Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • 2 Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • 3 Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • 4 Department of Molecular Medicine, Inha University College of Medicine, 100 Inha-ro, Nam-gu, Incheon 22212, Korea.
  • 5 Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • 6 Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • 7 Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. jerry.shay@utsouthwestern.edu.
PMID: 27798265 DOI: 10.1126/scitranslmed.aaf8127
Abstract

Mutations in the adenomatous polyposis coli (APC) gene are common in colorectal Cancer (CRC), and more than 90% of those mutations generate stable truncated gene products. We describe a chemical screen using normal human colonic epithelial cells (HCECs) and a series of oncogenically progressed HCECs containing a truncated APC protein. With this screen, we identified a small molecule, TASIN-1 (truncated APC selective inhibitor-1), that specifically kills cells with APC truncations but spares normal and Cancer cells with wild-type APC. TASIN-1 exerts its cytotoxic effects through inhibition of Cholesterol biosynthesis. In vivo administration of TASIN-1 inhibits tumor growth of CRC cells with truncated APC but not APC wild-type CRC cells in xenograft models and in a genetically engineered CRC mouse model with minimal toxicity. TASIN-1 represents a potential therapeutic strategy for prevention and intervention in CRC with mutant APC.

Figures
Products